Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342) | Zendy

José CastilloMancilla | Zendy; Christina L. Aquilante | Zendy; Michael F. Wempe | Zendy; Laura Smeaton | Zendy; Cynthia Firnhaber | Zendy; Alberto M. LaRosa | Zendy; Nagalingeswaran Kumarasamy | Zendy; Adriana Andrade | Zendy; Gautam Baheti | Zendy; Courtney V. Fletcher | Zendy; Thomas Campbell | Zendy; David W. Haas | Zendy; Samantha MaWhinney | Zendy; Peter L. Anderson | Zendy

Open Access

Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342)

Author(s) -

José CastilloMancilla,

Christina L. Aquilante,

Michael F. Wempe,

Laura Smeaton,

Cynthia Firnhaber,

Alberto M. LaRosa,

Nagalingeswaran Kumarasamy,

Adriana Andrade,

Gautam Baheti,

Courtney V. Fletcher,

Thomas Campbell,

David W. Haas,

Samantha MaWhinney,

Peter L. Anderson

Publication year - 2016

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkw005

Subject(s) - atazanavir , emtricitabine , efavirenz , population , medicine , pharmacokinetics , pharmacology , slco1b1 , ritonavir , human immunodeficiency virus (hiv) , pharmacogenetics , biology , viral load , virology , antiretroviral therapy , genotype , genetics , environmental health , gene

The multinational PEARLS (ACTG A5175) study, conducted mainly in resource-limited settings, identified an increased treatment failure rate among HIV-infected individuals randomized to once-daily unboosted atazanavir, didanosine-EC, and emtricitabine compared with efavirenz-based regimens. We evaluated associations between selected human genetic polymorphisms and atazanavir pharmacokinetics in PEARLS.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research